Broad Spectrum AI Designed Antibiotics for AMR
AINovo has used our proprietary AI platform to design novel biologic therapeutics which show broad-spectrum activity against clinical strains of AMR pathogens.
AI-designed molecules show broad spectrum activity for AMR Pathogens in vitro, synergy with existing antibiotics, variety of formulations possible
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
- OTHER / NA
- CARB-X
- FIND
- GARDP
- REPAIR
Infectious disease area:
- BSI
- RTI
- SSTI
- SSI
- UTI
- STI
- GII
- CNSI
- IAI
Geographic origin:
- North America
- South America
- Eurasia
- Africa
- Oceania
N.A.
AINovo has developed a proprietary artificial intelligence platform to design protein-based medicines &diagnostics for oncology & infectious diseases.
Partnerships with biopharma and research institutions for further development of our AMR assets, Technology-based partnerships with biopharma for joint development of novel molecules through AINovo Biotech’s artificial intelligence platform
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!